Last reviewed · How we verify

NCT03601845: MRE-IA

MRE-IA in Liver Disease and Neurovascular Imaging

Completed NA Last updated 11 February 2020
What this trial tests

NA trial testing Stimuli in Diffuse and Focal Liver Diseases, Cerebral Function in 59 participants. Completed in 1 July 2019.

Timeline
31 January 2019
Primary endpoint
1 July 2019
1 July 2019

Quick facts

Lead sponsorUniversité de Sherbrooke
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment59
Start date31 January 2019
Primary completion1 July 2019
Estimated completion1 July 2019
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Université de Sherbrooke — full company profile →

Who can join

Adults 18 to 100, any sex, with Diffuse and Focal Liver Diseases, Cerebral Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this research project is to develop Magnetic Resonance Elastography by Intrinsic Activation (MRE-IA) imaging methods at two imaging centers (CRCHUS and CRCHUM) for use in ongoing studies in liver disease and neurovascular imaging. MRE is a developing MR imaging modality that provides detailed maps of tissue's mechanical properties, based on displacement measurements made during the propagation of low amplitude vibrations through the region of interest. MRE-IA uses the pressure pulses of the cardiac cycle to induce the vibrations needed for MRE image reconstruction. MRE-IA has already been demonstrated based on the use of existing, clinically approved MR imaging sequences, and once this capability has been established at the two centers, initial trials will be done to demonstrate the method's potential in liver and neurovascular imaging. In the case of the liver, this pilot project funding will be used to perform MRE-IA imaging in patients with chronic liver disease and focal liver lesions. Results will be analyzed to establish the relationship between the mechanical properties mentioned above and disease stage. In the neurovascular case, imaging will be conducted under basic visual and motor stimulus conditions in healthy subjects, and results compared non-stimulus control images to determine changes in the above properties based on brain function. In addition, MRE-IA images will be compared with BOLD imaging to investigate the role of fluid conductivity in fMRI results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Stimuli

Trials testing the same drug.

Other Université de Sherbrooke trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing